QDEL Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $631 million, up 2% year-over-year (constant currency).

Revenue Growth (excluding China): 6%.

Adjusted EBITDA: $129 million, a 21% increase with an EBITDA margin of 20%, up 310 basis points.

Adjusted EPS: $0.13.

Operating Cash Flow: Negative $111 million; Free Cash Flow: Negative $136 million, impacted by a $25 million payment related to a terminated joint business arrangement.

Net Debt Leverage: 4.3x adjusted EBITDA.

2Strategic Updates and Business Highlights

New CFO: Micah Young joins the team, emphasizing cash conversion and operational improvements.

Core Business Performance: Strong demand across labs (9% growth) and immunohematology (5% growth) outside of China.

Neulixa Platform: Progress on the commercialization of the Lex point-of-care molecular platform, with positive early customer engagement.

Operational Improvements: Focus on productivity, disciplined expense management, and resource allocation to high-return opportunities.

3Forward Guidance and Outlook

Revised Full-Year Revenue Guidance: Expected to be between $2.52 billion and $2.6 billion, reflecting ongoing challenges in China and a cautious respiratory season forecast.

Adjusted EBITDA Guidance: Revised to $540 million to $560 million, with an EBITDA margin of 21% to 22%.

Adjusted EPS Guidance: Expected in the range of $0.65 to $0.90.

Withdrawal of Free Cash Flow Guidance: Due to uncertainties in market conditions and working capital implications.

4Bad News, Challenges, or Points of Concern

China Revenue Decline: Revenue in China fell 23% year-over-year due to uncertainty around IVD pricing guidelines, affecting customer purchasing behavior.

Soft Respiratory Market: Lower test positivity rates compared to 2025, with expectations for a below-average flu season.

Operational Risks: Ongoing uncertainty regarding the timing and impact of market changes in China and respiratory season dynamics, leading to a more cautious outlook.

5Notable Q&A Insights

Balance Sheet Leverage: Micah Young emphasized improving cash conversion and reducing leverage through better working capital management and capital allocation.

Speculation on Business Divestitures: Management refrained from commenting on rumors regarding the sale of the point-of-care business, focusing instead on maximizing long-term shareholder value.

Respiratory Season Forecast: Management indicated a shift to a more conservative approach in forecasting respiratory demand, citing lower positivity rates and data from the Southern Hemisphere as influencing factors. Overall, while QDEL demonstrated solid performance outside of China, significant challenges remain, particularly in the Chinese market and the respiratory segment, prompting a cautious outlook for the remainder of 2026.